June 07, 2022
Article
Potential biomarkers of overall survival outcomes have been identified in an exploratory post-hoc analysis of the phase 3 TITAN trial.
May 16, 2022
Article
Neoadjuvant axitnib demonstrated significant reductions in tumor size and complexity, allowing for partial nephrectomy in a subgroup of patients with renal cell carcinoma.
February 20, 2022
Article
NeoAvAx trial results show that neoadjuvant avelumab/axitinib may be beneficial to patients with renal cell carcinoma.
February 18, 2022
Article
Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.
September 25, 2021
Article
A phenomenon known as the “obesity paradox,” has been reported in prostate cancer as well as other genitourinary malignancies.
September 19, 2021
Article
According to updated data from the phase 1b COSMIC-021 trial, treatment with cabozantinib and atezolizumab continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, including those with high-risk clinical features.